These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28624380)

  • 1. Plasma Phospholipids and Sphingolipids Identify Stent Restenosis After Percutaneous Coronary Intervention.
    Cui S; Li K; Ang L; Liu J; Cui L; Song X; Lv S; Mahmud E
    JACC Cardiovasc Interv; 2017 Jul; 10(13):1307-1316. PubMed ID: 28624380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary in-stent restenosis: predisposing clinical and stent-related factors, diagnostic performance and analyses of inaccuracies in 320-row computed tomography angiography.
    Wan YL; Tsay PK; Chen CC; Juan YH; Huang YC; Chan WH; Wen MS; Hsieh IC
    Int J Cardiovasc Imaging; 2016 Jun; 32 Suppl 1():105-15. PubMed ID: 27106698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentially expressed miR-152, a potential biomarker for in-stent restenosis (ISR) in peripheral blood mononuclear cells (PBMCs) of coronary artery disease (CAD) patients.
    Maheronnaghsh M; Niktab I; Enayati S; Amoli MM; Hosseini SK; Tavakkoly-Bazzaz J
    Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1137-1147. PubMed ID: 33712363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
    Shen Y; Li C; Zhang RY; Zhang Q; Shen WF; Ding FH; Lu L
    Int J Cardiol; 2017 Feb; 228():129-136. PubMed ID: 27863353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of high level of hs-CRP with in-stent restenosis: A case-control study.
    Baktashian M; Saffar Soflaei S; Kosari N; Salehi M; Khosravi A; Ahmadinejad M; Moohebati M; Ebrahimi M; Rahmani F; Khameneh-Bagheri R; Ahmadi M; Sadabadi F; Tayefi M; Bazhdanzadeh S; Ferns GA; Hashemi SM; Pasdar A; Ghayour-Mobarhan M
    Cardiovasc Revasc Med; 2019 Jul; 20(7):583-587. PubMed ID: 30232022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs.
    He YH; Wang XQ; Zhang J; Liu ZH; Pan WQ; Shen Y; Zhu ZB; Wang LJ; Yan XX; Yang K; Zhang RY; Shen WF; Ding FH; Lu L
    Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):717-729. PubMed ID: 28183701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating level of microRNA-142-5p is a potential biomarker for predicting in-stent restenosis: a case-control study.
    Pan CH; Chien SC; Chen CJ; Shih CM; Hsieh MH; Huang CY; Bi WF; Chan CS; Kao YT; Hsiao CY; Chiang SJ; Chiang KH; Huang JH; Liu YR; Luo JD; Huang HY; Wu CH
    BMC Cardiovasc Disord; 2021 Feb; 21(1):77. PubMed ID: 33557763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of in-stent neoatherosclerosis and tissue characteristics between early and late in-stent restenosis in second-generation drug-eluting stents: an optical coherence tomography study.
    Sabbah M; Kadota K; El-Eraky A; Kamal HM; Abdellah AT; El Hawary A
    Int J Cardiovasc Imaging; 2017 Oct; 33(10):1463-1472. PubMed ID: 28444549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of M2BP in predicting in-stent restenosis in patients after coronary drug-eluting stent implantation.
    Yang L; Zhu H; Sun Y; Yan P; Song X; Xu F; Yuan H; Chen L
    Clin Cardiol; 2022 Mar; 45(3):308-314. PubMed ID: 35032135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors for functionally significant in-stent restenosis: an integrated analysis using coronary angiography, IVUS, and myocardial perfusion imaging.
    Kang SJ; Cho YR; Park GM; Ahn JM; Han SB; Lee JY; Kim WJ; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Mintz GS; Park SJ
    JACC Cardiovasc Imaging; 2013 Nov; 6(11):1183-90. PubMed ID: 24229771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preprocedural red blood cell distribution width predicts bare metal stent restenosis.
    Yildiz A; Tekiner F; Karakurt A; Sirin G; Duman D
    Coron Artery Dis; 2014 Sep; 25(6):469-73. PubMed ID: 24614629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents.
    Katsaros KM; Kastl SP; Krychtiuk KA; Hutter R; Zorn G; Maurer G; Huber K; Wojta J; Christ G; Speidl WS
    EuroIntervention; 2014 Jun; 10(2):224-30. PubMed ID: 24168783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.